<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30101">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01900717</url>
  </required_header>
  <id_info>
    <org_study_id>Bedenne PHRC K 2010.</org_study_id>
    <secondary_id>2010-022080-34</secondary_id>
    <nct_id>NCT01900717</nct_id>
  </id_info>
  <brief_title>Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)</brief_title>
  <acronym>Prodige20</acronym>
  <official_title>Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate tolerance to and efficacy of bevacizumab in the treatment of MCRC in elderly
      patients, we propose a phase II randomised study comparing a chemotherapy + bevacizumab arm
      with a chemotherapy alone arm in the first-line treatment of MCRC in patients aged 75 years
      and older.

      This study is destined to continue as a phase III trial if both arms meet the selection
      criteria to show or not the benefits of treatment with bevacizumab combined with
      chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Initial examination</measure>
    <time_frame>21 days before the first course of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>thoraco-abdomino-pelvic tomodensitometry or thoracic tomodensitometry and abdomino-pelvic MRI with identification and measurement of the target tumors according to RECIST (Response Evaluation Criteria in Solid Tumors
)criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial examination</measure>
    <time_frame>14 days before inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Medical history, clinical examination (HR, arterial blood pressure
, temperature, weight, height, Eastern Cooperative Oncology Group performance status),
measurement of body surface area, ECG
completion of questionnaire by the patient (annexe 1),
completion of geriatric questionnaire &quot;team&quot; (annexe 2)
biological examination including:
full blood count-platelets
blood electrolyte panel, creatinemia
Albumin
ASAT, ALAT, PAL, GGT, total and conjugated bilirubin
CEA, CA 19.9, LDH markers
balanced INR for patients on AVK
Urinary dip with 24-hour proteinuria if &gt; 1+
Measurement of  creatinine clearance using the Cockcroft formula (in men: (140-age) x weight (kg)/0.814 x creatinemia (μmol), in women: (140-age) x weight (kg)/0.85 x creatinemia (μmol)),
In the absence of a cardiological examination in the year before or in the case of a history of severe cardiovascular disease: consultation in cardiology.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Metastatic Colorectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>chimiotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LV5FU2 simplified,
5-fluorouracil/leucovorin with oxaliplatin 4 (FOLFOX) simplified,
fluorouracil, leucovorin, and irinotecan(FOLFIRI) modified.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemiotherapy + bevacizumab 5 mg/kg/ 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LV5FU2 simplified,
FOLFOX 4 simplified,
FOLFIRI modified.
Bevacizumab 5 mg/kg/ 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified</intervention_name>
    <arm_group_label>chimiotherapy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks</intervention_name>
    <arm_group_label>chemiotherapy + bevacizumab 5 mg/kg/ 2 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 75 years or older

          -  ECOG ≤2

          -  histologically proven unresectable metastatic colorectal adenocarcinoma

          -  Measurable lesion according to RECIST criteria

          -  Absence of prior chemotherapy for metastatic disease. Adjuvant chemotherapy following
             resection of the primary tumor is authorized if completed more than 6 months
             previously

          -  Patients treated with anticoagulants (coumadin, warfarin) can be included if close
             surveillance of the INR can be ensured. A change to low-molecular-weight heparin is
             preferable as long as the indications are respected

          -  Completed geriatric self‐questionnaire

          -  Completed &quot;Team&quot; geriatric questionnaire (including Spitzer QoL Index)

          -  Written informed consent

        Exclusion Criteria:

          -  Estimated life expectancy &lt; 3 months

          -  Non-resolved intestinal occlusion or sub‐occlusion

          -  Cerebral metastasis

          -  Other evolutive malignant tumor (non-stabilized cancer for less than 2 years)

          -  Evolutive gastroduodenal ulcer, wound or bone fracture

          -  Active heart disease: uncontrolled hypertension, myocardial infarction In the
             previous 6 months, angina, non-compensated congestive heart failure

          -  Major surgery, except for biopsy, or irradiation in the 4 weeks preceding the start
             of treatment

          -  Polynuclear neutrophils &lt;1500/mm3, platelets &lt;100 000/mm3 or 24-h proteinuria  &gt; 1g

          -  History of arterial thromboembolic event (cerebrovascular accident, transient
             ischemic attack, subarachnoid hemorrhage) in the 12 months preceding the first dose
             of bevacizumab

          -  History of distal or visceral ischemia ≥ grade 2 in the 12 months preceding the first
             dose of bevacizumab

          -  History of life-threatening pulmonary embolism in the 6 months preceding the first
             dose of bevacizumab

          -  Impossibility to ensure regular follow-up
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>July 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
